AR003589A1 - Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido. - Google Patents

Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido.

Info

Publication number
AR003589A1
AR003589A1 ARP960104362A AR10436296A AR003589A1 AR 003589 A1 AR003589 A1 AR 003589A1 AR P960104362 A ARP960104362 A AR P960104362A AR 10436296 A AR10436296 A AR 10436296A AR 003589 A1 AR003589 A1 AR 003589A1
Authority
AR
Argentina
Prior art keywords
peptide
cosmetic composition
cosmetic
preparation
effective amount
Prior art date
Application number
ARP960104362A
Other languages
English (en)
Original Assignee
Oréal L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oréal L filed Critical Oréal L
Publication of AR003589A1 publication Critical patent/AR003589A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a la utilización a título de principio activo, en un medio fisiológicamente aceptable, en una composición cosmética o para lapreparación de un medicamento, de una cantidad eficaz de al menos un péptido que contiene eltri péptido Lisina-Prolina-Valina, o de cualquier equivalentebiológico funcional, en la cual el residuo Prolina se encuentra bajo la forma de su isómero óptico dextrogiro, destinada a tratar la inflamación. Lainvención se refiere igualmente a unproced imiento de tratamiento cosmético.
ARP960104362A 1995-09-19 1996-09-16 Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido. AR003589A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9510977A FR2738746B1 (fr) 1995-09-19 1995-09-19 Utilisation d'au moins un peptide dans une composition cosmetique ou pour la preparation d'un medicament

Publications (1)

Publication Number Publication Date
AR003589A1 true AR003589A1 (es) 1998-08-05

Family

ID=9482701

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960104362A AR003589A1 (es) 1995-09-19 1996-09-16 Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido.

Country Status (12)

Country Link
US (2) US20050026845A1 (es)
EP (1) EP0764444B1 (es)
JP (1) JP2831979B2 (es)
AR (1) AR003589A1 (es)
CA (1) CA2185932C (es)
DE (1) DE69619753T2 (es)
ES (1) ES2174039T3 (es)
FR (1) FR2738746B1 (es)
MX (1) MX9710252A (es)
PL (1) PL186767B1 (es)
RU (1) RU2180590C2 (es)
WO (1) WO1997010838A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2784028B1 (fr) 1998-10-01 2003-02-07 Oreal Utilisation d'un peptide prevenant les reactions d'intolerance de la peau, notamment dans des compositions cosmetiques
US6803044B1 (en) 1999-03-24 2004-10-12 Zengen, Inc. Antimicrobial and anti-inflammatory peptides for use in human immunodeficiency virus
US6800291B1 (en) 1999-03-24 2004-10-05 Zengen, Inc. Uro-genital condition treatment system
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
US7402559B2 (en) 1999-03-24 2008-07-22 Msh Pharma, Incorporated Composition and method of treatment for urogenital conditions
PT1092427E (pt) * 1999-10-04 2007-08-06 Oreal Utilização de um péptido para prevenir as reacções de intolerância da pele em especial nas composições cosméticas
US6780838B2 (en) 2001-01-29 2004-08-24 Zengen, Inc. Compounds for treating fungal pathologies of the oral cavity
US6894028B2 (en) 2001-04-06 2005-05-17 Zengen, Inc. Use of KPV tripeptide for dermatological disorders
FR2826263B1 (fr) * 2001-06-26 2005-02-25 Oreal Composition cosmetique ou dermatologique comprenant une association entre un compose inhibiteur de l'elastase de la famille des n-acylaminoamides et au moins un compose anti-inflammatoire
FR2826580B1 (fr) * 2001-06-29 2005-09-30 Oreal Utilisation du tripeptide lys-pro-val (kpv) pour favoriser le renouvellement epidermique et la micro-cicatrisation cutanee superficielle et/ou ameliorer l'aspect esthetique des plaies et cicatrices
FR2826581B1 (fr) * 2001-06-29 2005-10-07 Oreal Utilisation du tripeptide lys-pro-val (kpv) dans le traitement des melanomes
FR2827170B1 (fr) * 2001-07-13 2004-07-16 Soc Extraction Principes Actif Utilisation de peptides pour augmenter l'adhesion cellulaire
US7115574B2 (en) 2001-12-10 2006-10-03 Zengen, Inc. System and method for support legacy operating system booting in a legacy-free system
US6939846B2 (en) 2001-12-17 2005-09-06 Zengen, Inc. Use of a polypeptide for treatment of pruritis in animals
WO2004043482A1 (fr) * 2002-11-08 2004-05-27 Societe D'extraction Des Principes Actifs (Vincience) Composition cosmetique ou pharmaceutique comprenant des peptides, possedant le motif arg-gly-ser
FR2846883B1 (fr) * 2002-11-08 2004-12-24 Vincience Composition cosmetique comprenant, comme ingredient actif, au moins un peptide et utilisation de ce peptide
WO2005120554A1 (en) 2004-06-14 2005-12-22 Cognis France S.A.S. Cosmetic preparations containing pth fragments
US7300649B2 (en) 2005-02-11 2007-11-27 Genepharm, Inc. Cosmetic and cosmeceutical compositions for restoration of skin barrier function
JP6313541B2 (ja) * 2009-12-08 2018-04-18 アーエムシルク ゲーエムベーハー シルクタンパク質コーティング
US11717593B2 (en) 2013-03-13 2023-08-08 Avery Dennison Corporation Improving adhesive properties
PL3049428T3 (pl) * 2013-09-23 2019-07-31 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Tripeptydy przeciwzapalne
KR102208853B1 (ko) * 2018-05-08 2021-01-28 오션펩 주식회사 주름개선 효능을 갖는 펩티드

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028592A (en) * 1986-08-08 1991-07-02 Lipton James M Antipyretic and anti-inflammatory peptides
US5157023A (en) * 1984-08-21 1992-10-20 Lipton James M Antipyretic and anti-inflammatory lys pro val compositions and method of use
US4878744A (en) * 1985-12-30 1989-11-07 Capitol Records, Inc. Three dimensional reflex lens systems
DE3778550D1 (de) * 1986-08-08 1992-05-27 Univ Texas Fieber- und entzuendungshemmende peptide.
GB8807427D0 (en) * 1988-03-28 1988-05-05 National Biological Standards Board Peptides
DE68923572T2 (de) * 1988-03-28 1996-01-18 British Tech Group Peptide.
FR2784028B1 (fr) * 1998-10-01 2003-02-07 Oreal Utilisation d'un peptide prevenant les reactions d'intolerance de la peau, notamment dans des compositions cosmetiques

Also Published As

Publication number Publication date
CA2185932C (fr) 2003-11-11
PL324485A1 (en) 1998-05-25
PL186767B1 (pl) 2004-02-27
US20050026845A1 (en) 2005-02-03
CA2185932A1 (fr) 1997-03-20
JP2831979B2 (ja) 1998-12-02
FR2738746B1 (fr) 1997-11-14
RU2180590C2 (ru) 2002-03-20
ES2174039T3 (es) 2002-11-01
EP0764444A1 (fr) 1997-03-26
MX9710252A (es) 1998-03-31
FR2738746A1 (fr) 1997-03-21
EP0764444B1 (fr) 2002-03-13
DE69619753D1 (de) 2002-04-18
JPH09124502A (ja) 1997-05-13
WO1997010838A1 (fr) 1997-03-27
US20080038208A1 (en) 2008-02-14
DE69619753T2 (de) 2002-08-08

Similar Documents

Publication Publication Date Title
AR003589A1 (es) Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido.
ES2102921T3 (es) Utilizacion de derivados de la hormona estimuladora de los melanocitos de tipo alfa para estimular el crecimiento de los cabellos.
AR002023A1 (es) Utilizacion no terapeutica de por lo menos un antagonista del peptido derivado del gen de la calcitonina es decir un antagonista de cgrp , utilizacion de dicho antagonista para la preparacion de una composicion que contiene un medio dermatologicamente o farmaceuticamente aceptable, procedimiento de tratamiento cosmetico, y composicion topica que comprende dicho antagonista
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
AR005940A1 (es) Composicion cosmetica de fijacion y brillo en aerosol, y procedimiento
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
AR003989A1 (es) Composicion cosmetica o farmaceutica y procedimiento de tratamiento cosmetico, excluido tdo tratamiento terapeutico que utiliza la composicion cosmetica.
GT199700141A (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas.
EE04111B1 (et) Raku adhesiooni inhibiitorid, nende kasutamine janeid sisaldavad farmatseutilised kompositsioonid
ES2152710T3 (es) Preparados cosmeticos para aplicacion topica que contienen extractos de phyllanthus emblica y centella asiatica y/o bacopa monnieri.
AR002974A1 (es) Utilización de por lo menos un antagonista de cgrppara la preparación de una composición cosmética, farmacéutica y/o dermatológica para tratar las manchas rojas cutáneas de origen neurógeno, composición obtenida y procedimiento de tratamiento cosmético empleando dicho antagonista.
AR016751A1 (es) Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
ES2151083T3 (es) Composiciones orales que contienen ondansetron.
RU95106674A (ru) Полиеновые соединения, фармацевтическая и косметическая композиция на их основе
DK0832081T3 (da) Bicykliske-aromatiske forbindelser
HUP0300917A2 (hu) Bradikardiakumok alkalmazása hipertrófiával társult miokardiális betegségek kezelésére és ezeket tartalmazó gyógyszerkészítmények
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
AR005860A1 (es) Compuestos heterociclicos aromaticos, composiciones farmaceuticas y cosmeticas que los contienen, y su utilización.
AR004326A1 (es) Utilizacion de al menos un antagonista de tnf-alfa, composicion cosmetica, farmaceutica o dermatologica que contiene dicho antagonista y procedimiento detratamiento cosmetico empleando dicho antagonista.
AR003901A1 (es) Composicion para el tratamiento de las fibras queratinicas que comprende al menos un polimero fijante y al menos un compuesto de tipo ceramida yprocedimientos.
ATE302210T1 (de) Histogranin peptide und deren analgetische verwendung
ES2041243T3 (es) Aplicacion de por lo menos un principio activo inhibidor o destructor de por lo menos un ser vivo unicelular o virus.
ES2191083T3 (es) Composicion para limpiar y/o desinfectar instrumentos para uso medico.
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.

Legal Events

Date Code Title Description
FC Refusal